Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow LENZ Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for LENZ Therapeutics, Inc.

LENZ

LENZ Therapeutics, Inc.

About LENZ Therapeutics, Inc.

Lenz Therapeutics develops innovative ophthalmic therapies, focusing on presbyopia. Its lead product, LNZ100, is a once-daily, aceclidine-based eye drop designed to improve near vision safely and effectively for a broad age range. The company aims to become a category leader by leveraging proprietary technology, pursuing FDA approval, and building a specialized commercial team to serve presbyopes globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from LENZ Therapeutics, Inc.

1
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports $1.9 Million Revenue in Q1 2026, Net Loss of $41.5 Million

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports Fiscal Year 2025 Results and VIZZ Commercial Launch

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports Q3 2025 Financial Results with Revenue Growth from VIZZ Launch

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports $5 Million Revenue in Q2 2025, Faces $14.9 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports $14.6 Million Net Loss in Q1 2025, Focuses on LNZ100 Commercialization

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports $49.77 Million Net Loss for 2024, Prepares for LNZ100 Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
LENZ Therapeutics, Inc. LENZ Therapeutics Reports Improved Liquidity, Reduced Losses Following Merger and PIPE Financings

Via official filing (AI summary) | over 1 year ago | 0 comments